-- 輝瑞（PFE）週三表示，一項評估Elrexfio治療成人多發性骨髓瘤的3期臨床試驗顯示，與達雷妥尤單抗聯合泊馬度胺和地塞米松相比，Elrexfio在主要終點——無進展生存期方面取得了顯著改善。 該公司表示，該候選藥物的安全性和耐受性與其已知的安全性特徵相符，並補充說，大多數接受該藥物治療的患者病情仍未進展。 該公司表示，該研究仍在進行中，以評估總生存期，這是一項關鍵的次要終點，在進行中期分析時，該終點的數據尚未成熟。
Price: $26.43, Change: $-0.05, Percent Change: -0.21%
General Motors (GM) could beat its 2026 outlook if the economy steadies, with further earnings growth likely into 2027 from cost control, electric vehicle profitability, stronger vehicle mix, and share buybacks, UBS said in a note emailed Wednesday.Investor concerns over commodity costs and demand risk misses General Motors' stronger execution, flexibility and spending control, according to the note.General Motors' outlook has some elements of conservatism because the company has not included a possible restocking of high-profit pickups and SUVs in its guidance, UBS said.The firm noted that possible USMCA trade talks are more likely to help the company than hurt it, though not included in its outlook.UBS kept its buy rating on General Motors and lowered its price target to $102 from $105.Price: $76.08, Change: $-2.87, Percent Change: -3.63%
Price: $90.23, Change: $-10.41, Percent Change: -10.34%